EP4422683A4 - Kits und behälter zur behandlung von vimentinexprimierenden tumoren - Google Patents

Kits und behälter zur behandlung von vimentinexprimierenden tumoren

Info

Publication number
EP4422683A4
EP4422683A4 EP21962721.3A EP21962721A EP4422683A4 EP 4422683 A4 EP4422683 A4 EP 4422683A4 EP 21962721 A EP21962721 A EP 21962721A EP 4422683 A4 EP4422683 A4 EP 4422683A4
Authority
EP
European Patent Office
Prior art keywords
vimentin
kits
containers
treatment
expressing tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21962721.3A
Other languages
English (en)
French (fr)
Other versions
EP4422683A1 (de
Inventor
Ivan Babic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nascent Biotech Inc
Original Assignee
Nascent Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nascent Biotech Inc filed Critical Nascent Biotech Inc
Publication of EP4422683A1 publication Critical patent/EP4422683A1/de
Publication of EP4422683A4 publication Critical patent/EP4422683A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21962721.3A 2021-10-29 2021-10-29 Kits und behälter zur behandlung von vimentinexprimierenden tumoren Pending EP4422683A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/057313 WO2023075790A1 (en) 2021-10-29 2021-10-29 Kits and containers for treating vimentin expressing tumors

Publications (2)

Publication Number Publication Date
EP4422683A1 EP4422683A1 (de) 2024-09-04
EP4422683A4 true EP4422683A4 (de) 2025-07-30

Family

ID=86158437

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21962721.3A Pending EP4422683A4 (de) 2021-10-29 2021-10-29 Kits und behälter zur behandlung von vimentinexprimierenden tumoren

Country Status (6)

Country Link
EP (1) EP4422683A4 (de)
JP (1) JP7815590B2 (de)
CN (1) CN116367853A (de)
AU (1) AU2021471595A1 (de)
CA (1) CA3236114A1 (de)
WO (1) WO2023075790A1 (de)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170073400A1 (en) * 2015-09-11 2017-03-16 Nascent Biotech, Inc. Enhanced delivery of drugs to the brain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2895198A1 (en) * 2012-12-20 2014-06-26 Medimmune, Llc Liquid antibody formulation with improved aggregation properties
MY175472A (en) 2013-09-27 2020-06-29 Genentech Inc Anti-pdl1 antibody formulations
JP6634394B2 (ja) 2014-06-26 2020-01-22 アムジェン インコーポレイテッド タンパク質製剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170073400A1 (en) * 2015-09-11 2017-03-16 Nascent Biotech, Inc. Enhanced delivery of drugs to the brain

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Pharmaceutical Dosage Forms, Parental Medications Third Edition, Volume 1 Formulation and Packaging", 1 January 2010, article ZHU GAOZHONG ET AL: "Chapter 9 Formulation of protein- and peptide-based parenteral products", pages: 222 - 253, XP055874783 *
MARK C. GLASSY ET AL: "Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab", HUMAN ANTIBODIES, vol. 18, no. 4, 1 January 2009 (2009-01-01), AMSTERDAM, NL, pages 127 - 137, XP055518853, ISSN: 1093-2607, DOI: 10.3233/HAB-2009-0209 *
See also references of WO2023075790A1 *

Also Published As

Publication number Publication date
CN116367853A (zh) 2023-06-30
JP2024544358A (ja) 2024-11-29
WO2023075790A1 (en) 2023-05-04
EP4422683A1 (de) 2024-09-04
CA3236114A1 (en) 2023-05-04
JP7815590B2 (ja) 2026-02-18
AU2021471595A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
MA52232A (fr) Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
EP3908354A4 (de) Faserartige vorrichtungen zur behandlung von gefässdefekten
EP4467154A4 (de) Medikament zur behandlung oder prävention von krebs
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
EP3937932A4 (de) Cgas-inhibitoren zur behandlung von autoimmunerkrankungen und krebsmetastasen
EP3765611A4 (de) Auf pcsk9 zielende oligonukleotide zur behandlung von hypercholesterinämie und zugehörigen störungen
EP3908601A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs
EP3766497A4 (de) Arzneimittel zur behandlung von husten
EP3863671A4 (de) Monoklonaler antikörper zur behandlung von akuter lymphoblastischer leukämie
EP3630080A4 (de) Verwendung von ezh2-inhibitoren zur behandlung von krebs
MA52961A (fr) Compositions et procédés pour la réduction ou le traitement d'une inflammation
EP3870104A4 (de) Verfahren und materialien zur behandlung von krebs
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
EP4138906A4 (de) Verfahren zur prophylaxe und behandlung von covid und covid-19
EP4149547A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP3727374A4 (de) Kombination aus einem anti-pd-l1-antikörper und einem ido1-inhibitor zur behandlung von krebs
EP3801478A4 (de) Verfahren und zusammensetzungen zur prävention oder behandlung von calciphylaxie
EP4292596A4 (de) Verfahren und kombination zur behandlung von tumoren
EP3400942A4 (de) Verwendung von chinolin-derivaten zur behandlung von speiseröhrenkrebs und behandlungsverfahren, pharmazeutische zusammensetzung und kit dafür
EP4373525A4 (de) Krebsbehandlungskombinationen
MA55982A (fr) Composition pharmaceutique pour le traitement de tumeurs
EP4157341A4 (de) Peptide zur covid-19-prävention und -behandlung
EP4209216A4 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren
EP4097137A4 (de) Kombinationen von egfr-inhibitoren und ror1-inhibitoren zur behandlung von krebs

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240529

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40116094

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0039395000

Ipc: C07K0016180000

A4 Supplementary search report drawn up and despatched

Effective date: 20250630

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/18 20060101AFI20250624BHEP

Ipc: A61K 39/395 20060101ALI20250624BHEP

Ipc: A61K 39/00 20060101ALI20250624BHEP

Ipc: B32B 17/00 20060101ALI20250624BHEP

Ipc: B32B 27/36 20060101ALI20250624BHEP